Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) Q2 2023 Earnings Conference Call August 8, 2023 4:30 PM ET
Company Participants
Peter Vozzo - ICR Westwicke, IR
Jack Khattar - CEO
Tim Dec - CFO
Conference Call Participants
Andrew Tsai - Jefferies
David Amsellem - Piper Sandler
Operator
Good afternoon and welcome to Supernus Pharmaceuticals Second Quarter 2023 Financial Results Conference Call. At this time, all participants are in listen-only mode. Later, we will conduct a question-and-answer session, instructions will follow at that time. As a reminder, this conference call is being recorded.
I would now like to turn the conference over to Peter Vozzo of ICR Westwicke, Investor Relations representative for Supernus Pharmaceuticals. You may begin.
Peter Vozzo
Thank you, Steven. Good afternoon everyone and thank you for joining us today for Supernus Pharmaceuticals second quarter 2023 financial results conference call. Today, after the close of the market, the company issued a press release announcing these results.
On the call with me, today are Supernus' Chief Executive Officer, Jack Khattar; and Chief Financial Officer, Tim Dec. Today's call is being made available via the Investor Relations section of the company's website at ir.supernus.com.
During the course of this call, management may make certain forward-looking statements regarding future events and the company's future performance. These forward-looking statements reflect Supernus' current perspective on existing trends and information.
Any such forward-looking statements are not guarantees of future performance and involve risks and uncertainties, including those noted in the Risk Factors section of the company's latest SEC filings. Actual results may differ materially from those projected in these forward-looking statements.
For the benefit of those of you, who may be listening to the replay, this call is being held and recorded on August 8, 2023. Since then, the company may have made additional announcements related to the topics discussed. Please reference the company's most recent press releases and current filings with the SEC. Supernus declines any obligation to update these forward-looking statements, except as required by applicable securities laws.
I'll now turn the call over to Jack.
Jack Khattar
Thank you, Peter. Good afternoon everyone and thanks for taking the time to join us as we discuss our 2023 second quarter. Supernus continues to execute well during a transition year with the loss of exclusivity on its flagship brand Trokendi XR.
In the second quarter of this year, our growth products continued to deliver robust growth with Qelbree and GOCOVRI, achieving combined net sales of $60 million. This represents 67% growth compared to the same period last year and by far, exceeds the $52 million decline in Trokendi XR net sales in the second quarter compared to 2022.